Comparing analgesic efficacy of different regional blocks after total hip arthroplasty Authors: Dan-Feng Wang, Yong-Bao Lin, Fu-Shan Xue Published: 2025 To the Editor, By conducting a randomized controlled trial in a total of 60 participants who underwent total hip arthroplasty (THA) under general anesthesia, Baran et al. [1] demonstrated that the continuous pericapsular nerve group block (PENGB) was superior to the continuous supra-inguinal fascia iliaca compartment block (SIFICB) in terms of reducing postoperative pain and opioid consumption. Their results are not in agreement with the findings of Choi et al.’ study [2], in which the PENGB and SIFICB provide comparable analgesic efficacy and opioid consumption during postoperative 48 h. Other than the limitations described by Baran et al. in the discussion section, we noted several issues regarding the methodology and results of this study that need further discussion and clarifications. First, pain alleviation and physical function improvement are the common indications of THA, but Baran et al. [1] didn’t clearly describe whether the two groups were comparable with respect to preoperative pain, analgesic use, physical function and psychological disorders. Available literatures indicates that preoperative pain severity, pain catastrophizing scores, a history of long-term analgesic use, somatization, poor physical function, anxiety and depression are significantly associated with a worsened acute pain and an increased opioid consumption after THA [3, 4]. We are concerned that any significant between-group difference in these unknown factors would have biased the results of this study. Second, intravenous paracetamol was used as rescue analgesic when a pain score was > 4. It must be noticed that paracetamol only is a weak acting analgesic which is effective for mild to moderate pain. In the current enhanced recovery after hip surgery practices, paracetamol is a core component of the opioid-sparing multimodal analgesia schemes and is required to be given based on the scheduled dosing, rather than as a rescue analgesic on needed [5]. This design limitation may have impeded the generalization of their findings into the current enhanced recovery after orthopedic surgery practices. Third, the perineural catheters remained functional throughout 24 h postoperatively in the two groups. Bupivacaine 0.125% was continuously infused at 5 ml/hour via the perineural catheters, but the SIFICB group showed an increasing trend of pain intensities after 6 h and had median rest and movement pain scores of 4 or more at 12 and 24 h postoperatively. In contract, the PENGB group demonstrated a gradual decrease in median rest and movement pain scores after 6 h. We would like to know the reasons for these between-group differences of postoperative pain scores. Finally, total opioid consumption within 24 h postoperatively was significantly decreased in the PENGB group, but the net between-group difference of mean total opioid consumptions was 7.3, which does not exceed the recommended minimal clinically important difference, that is, 9 mg intravenous morphine [6]. This indicates that the between-group difference of postoperative total opioid consumption was statistically significant but clinically no-important. Furthermore, Baran et al. [1] didn’t assess the occurrence of postoperative moderate to severe pain and patient satisfaction with postoperative pain control in the two groups, though poorly controlled postoperative acute pain is significantly associated with delayed recovery and adverse outcomes after THA [5]. Thus, we argue that future large-scale clinical trials with rigorous design are needed to validate the results of this study.